

VOLUME 105 SUPPLEMENT 1992

Parasitology

Supplement to Parasitology 1992

Chemotherapy and the immune system

EDITED BY L. H. CHAPPELL & M. J. DOENHOFF

CAMBRIDGE UNIVERSITY PRESS

Subscriptions may be sent to any bookseller or subscription agent or direct to the publisher: Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 2RU. Subscriptions in the USA, Canada and Mexico should be sent to Cambridge University Press, Journals Department, 40 West 20th Street, New York, NY 10011-4211. All orders must be accompanied by payment. The subscription price of volumes 106 and 107, 1993 is £225 (US \$440 in the USA, Canada and Mexico), payable in advance, for ten parts plus supplements; separate parts cost £20 or US \$40 each (plus postage). Japanese prices for institutions (including ASP delivery) are available from Kinokuniya Company Ltd, P.O. Box 55, Chitose, Tokyo. Second class postage paid at New York, NY and at additional mailing offices. POSTMASTER: send address changes in USA, Canada and Mexico to *Parasitology*, Cambridge University Press, 110 Midland Avenue, Port Chester, New York, NY 10573-9864.

ISBN 0 521 44835 2

© Cambridge University Press 1992

The Pitt Building, Trumpington Street, Cambridge CB2 1RP
40 West 20th Street, New York, NY 10011-4211, USA
10 Stamford Road, Oakleigh, Melbourne 3166, Australia

Printed in Great Britain by the University Press, Cambridge

Parasitology

Volume 105 Supplement 1992

Chemotherapy and the immune system

EDITED BY

L. H. CHAPPELL AND M. J. DOENHOFF



CAMBRIDGE
UNIVERSITY PRESS

Contents

<i>Preface</i> : Positive interactions between anti-infection drugs and the immune response: an emerging paradigm	S1	Anti-LFA-1 (anti-CD 11a) and anti-ICAM-1 (anti-CD54)	S17
<i>List of contributions</i>	S3	Cytokines as targets for mediators of immunosuppression	S18
Immunomodulatory agents in the laboratory and clinic	S5	MHC blocking peptides	S18
Introduction	S5	References	S18
Biologic response modifiers and the concept of adjuvants	S7	Cyclosporin A: antiparasite drug, modulator of the host-parasite relationship and immunosuppressant	S25
Adjuvants of gram-negative origin	S7	Summary	S25
Development of LPS derivatives with reduced or non-pyrogenicity	S7	Introduction	S25
Adjuvants of gram-positive origin	S7	Protozoa	S25
Other adjuvants	S8	Antiprotozoal activity of cyclosporin A	S26
Cytokines	S8	Immunomodulation of protozoan infections by cyclosporin A	S27
Interferon-gamma (IFN- γ)	S8	Leishmaniasis	S27
Interleukin-1 (IL-1)	S8	Trypanosomiasis	S28
Interleukin-2 (IL-2)	S9	Giardiasis	S29
Interleukin-3 (IL-3)	S9	Theileriosis	S29
Interleukin-4 (IL-4)	S9	Combined antiprotozoal and immunomodulatory effects of cyclosporin A	S29
Interleukin-5 (IL-5)	S9	Toxoplasmosis	S29
Interleukin-6 (IL-6)	S10	Avian coccidiosis	S29
Tumor necrosis factor alpha (TNF- α)	S10	Other microorganisms	S30
Granulocyte-macrophage colony stimulating factor (GM-CSF)	S10	Helminth infections	S30
Mechanisms involved in non-specific pathogen destruction and/or inhibition	S10	Anthelmintic activity	S30
NO-mediated pathogen alteration	S10	Trematodes	S30
Oxidative burst	S11	Cestodes	S34
Inflammatory response	S11	Nematodes	S35
Immunosuppressive drugs	S12	Immunomodulatory activity of CsA in helminth infections	S35
Cytotoxic agents (antimetabolites and alkylating agents)	S12	Combined immunomodulatory and antiparasitic activity of CsA	S35
Azathioprine (Aza)	S12	Cyclosporin-binding proteins and possible mode of anthelmintic action	S36
RS-61443 and mycophenolic acid (MPA)	S12	Conclusions	S36
Bredinin (BR) = mizoribine	S12	Acknowledgement	S37
Brequinar sodium	S13	References	S37
Cyclophosphamide (Cy)	S13	Immune-dependent chemotherapy of schistosomiasis	S41
Methotrexate (MTX)	S13	Summary	S41
Corticosteroids	S13	Introduction	S41
Deoxyspergualin	S14	Demonstration of the immune-dependence of chemotherapy using immunosuppressed mice	S41
T-cell directed immunosuppressive drugs	S14	Praiquantel-induced exposure of surface antigens: an explanandum for immune-dependent chemotherapy	S42
Cyclosporin A and FK506	S14	Praiquantel-exposed surface antigens	S42
Rapamycin	S16		
Monoclonal antibodies	S16		
Anti-CD4	S17		
Anti-IL-2R	S17		
MAB against allelic MHC class II gene products	S17		
Anti-TCR	S17		

Further characterisation of two antigens involved in PZQ/antibody synergy	S44	Immune-dependence of chemotherapy in leishmaniasis	S73
Enhancement of schistosomicidal drug activity in vaccinated mice	S45	Immunocompetence and chemotherapy	S73
Conclusions and future prospects	S45	Combined immunochemotherapy	S74
Acknowledgements	S46	Conclusion and outlook	S75
References	S46	Acknowledgements	S76
		References	S76
Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug	S49	Interactions between chemotherapy and immunity in bovine theileriosis	S79
Summary	S49	Summary	S79
Diethylcarbamazine (DEC) and other anti-filarial drugs	S49	Introduction	S79
DEC has an indirect mode of action on filarial parasites	S50	Chemotherapy of theileriosis	S79
The microfilaricidal effect of DEC is independent of a specific antibody response	S51	Immunology of theileriosis	S80
The effect of DEC does not require complement	S51	Infection-and-treatment	S81
DEC effects on arachidonic acid metabolism may be the primary mode of action	S52	Conclusions	S82
DEC-mediated changes to vasculature	S53	Acknowledgements	S82
DEC promotion of host cell adhesion	S54	References	S82
DEC enhancement of platelet and granulocyte killing	S54	Viruses, chemotherapy and immunity	S85
Immunological side-effects of DEC administration	S55	Introduction	S85
T-cell reactivity after chemotherapy	S56	Antiretroviral agents	S85
Conclusions	S56	Interferons	S87
Acknowledgements	S57	Acyclovir	S89
References	S57	Ganciclovir	S90
		References	S90
Malaria: drug use and the immune response	S61	Chemotherapy and immunity in opportunistic parasitic infections in AIDS	S93
Introduction	S61	Summary	S93
Depression of leucocyte function by antimalarial drugs	S61	Introduction	S93
Anti-drug antibody responses	S62	The immune defects in AIDS	S93
Drug-induced antibody responses	S62	<i>Pneumocystis carinii</i>	S94
Chemoprophylaxis and the immune responses to vaccines	S63	<i>Toxoplasma gondii</i>	S95
Chemoprophylaxis and acquired immunity to malaria	S63	<i>Cryptosporidium</i> spp.	S95
Immune dependence of chemotherapy	S65	<i>Microsporidia</i> spp.	S96
Future considerations	S67	<i>Isospora belli</i>	S96
Acknowledgements	S68	<i>Leishmania</i> spp.	S96
References	S68	Other protozoa	S97
		Helminths	S98
Interactions between immunity and chemotherapy in the treatment of the trypanosomiasis and leishmaniasis	S71	<i>Sarcoptes scabiei</i>	S98
Summary	S71	Conclusion	S98
Introduction	S71	References	S98
Immune-dependence of chemotherapy in African trypanosomiasis	S71	Hypothesis: impaired immunity as a factor which contributes to the spread of drug-resistance	S103
		Summary	S103
		Introduction	S103
		The evidence	S103
		Mechanisms	S104
		Conclusions	S104
		Acknowledgements	S105
		References	S105
		Endpiece	S107